Although several attempts have been made in testing the effect of Defactinib in patients with malignant mesothelioma, due in part to the fact that merlin deficiency has been shown to predict FAK-inhibitor sensitivity [141], several trials were discontinued due to insufficient efficacy (NCT02004028, NCT01870609, and NCT02372227). The gene discussed is NF2; the disease is malignant mesothelioma.